Baillie Gifford & Co
KLDO

Baillie Gifford & Co’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Baillie Gifford & Co’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-733,525
Closed -$1.21M – 523
2022
Q1 		$1.21M Buy
733,525
+12,013
+2% +$21.4K ﹤0.01% 270
2021
Q4 		$1.72M Buy
721,512
+62,285
+9% +$254K ﹤0.01% 268
2021
Q3 		$3.6M Buy
659,227
+766
+0.1% +$4.75K ﹤0.01% 263
2021
Q2 		$4.9M Buy
658,461
+1,070
+0.2% +$7.58K ﹤0.01% 258
2021
Q1 		$5.33M Buy
657,391
+217,391
+49% +$2.37M ﹤0.01% 250
2020
Q4 		$4M Hold
440,000
– – ﹤0.01% 235
2020
Q3 		$4.87M Hold
440,000
– – ﹤0.01% 222
2020
Q2 		$3.27M Hold
440,000
– – ﹤0.01% 214
2020
Q1 		$2.71M Hold
440,000
– – ﹤0.01% 192
2019
Q4 		$2.21M Hold
440,000
– – ﹤0.01% 200
2019
Q3 		$3.31M Hold
440,000
– – ﹤0.01% 198
2019
Q2 		$5.1M Hold
440,000
– – 0.01% 200
2019
Q1 		$6.38M Buy
+440,000
New +$6.06M 0.01% 196

Other funds holding KLDO

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Baillie Gifford & Co's KLDO Position: Q2 2022 in Review

Baillie Gifford & Co sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 733,525 shares — an estimated $1.21M sold.

Baillie Gifford & Co first reported a position in KLDO in Q1 2019 and held it in 13 quarters. The position peaked at $6.38M in Q1 2019. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

  • Baillie Gifford & Co reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Baillie Gifford & Co sold 733,525 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $1.21M.
  • Baillie Gifford & Co first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2019 and held it in 13 quarters.
  • Baillie Gifford & Co's Kaleido Biosciences, Inc. Common Stock position peaked at $6.38M in Q1 2019.
  • 3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on Baillie Gifford & Co's 13F filing for Q2 2022, filed 8 Aug 2022.